Clinical Trials Directory

Trials / Terminated

TerminatedNCT04317586

Trident II Revision Outcomes Study

A Prospective, Post-market, Multi-center Evaluation of the Clinical Outcomes of the Trident II Acetabular Shell in a Revision Indication

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
17 (actual)
Sponsor
Stryker Orthopaedics · Industry
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to review the performance and success rate of an FDA cleared cementless hip replacement part called the Trident II Tritanium Acetabular Shell. The study will specifically look at the need to revise the hip replacement after 5 years. This will be compared to how much this happens in patients who have hip replacement with similar cementless acetabular shells.

Conditions

Interventions

TypeNameDescription
DEVICETrident II Tritanium Acetabular Shell for RevisionA hemispherical acetabular shell indicated for cementless application in a previously failed total hip arthroplasty (THA)

Timeline

Start date
2020-06-23
Primary completion
2023-01-27
Completion
2023-01-27
First posted
2020-03-23
Last updated
2023-12-01
Results posted
2023-12-01

Locations

10 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04317586. Inclusion in this directory is not an endorsement.